Market Herald logo


Be the first with the news that moves the market
  • Pharmaceutical company Starpharma has launched its VivaGel product in the U.K. 
  • Viva Gel is the company’s flagship product and its latest foray into the women’s health treatment industry
  • The product is being sold through pharmacy giant Mundipharma 
  • Starpharma’s share price is down nearly one per cent today, currently sitting at $1.42 cents per share

Starpharma has launched its flagship VivaGel product in the U.K.

The product is being sold through pharmacy giant Mundipharma, who is also launching VivaGel across Europe. Launches are also planned for Asia in the near future, dependent on regulatory approvals.

“Starpharma and Mundipharma are working closely together to bring this breakthrough product to European women suffering from BV,” Starpharma’s CEO Dr Jackie Fairley said.

The VivaGel products are non-antibiotic treatments for bacterial vaginosis. The product comes in gel form and as a condom.

Bacterial vaginosis is a common condition affecting women, caused by a build up various bacteria on the vagina. Globally, one in three women suffer from the condition.

Published in the International Journal of Microbiology, bacterial vaginosis is classified as a “global concern” based on its risk of spreading sexually transmitted diseases.

Starpharma and Mundipharma said the two companies are continuing to work on gaining regulatory approvals world-wide and continuing the roll out of its products.

Heading into the last hour of today’s trade, Starpharma’s share price is down 2.26 per cent, currently sitting at $1.30 per share.

SPL by the numbers
More From The Market Herald
The Market Herald Video

" Next Science’s (ASX:NXS) CEO submits resignation

Next Science’s (ASX:NXS) CEO has announced her intention to retire before June 30, 2023.
The Market Herald Video

" Race Oncology (ASX:RAC) completes first-phase Zantrene leukaemia trial

Cancer treatment company Race Oncology (ASX:RAC) has completed the latest stage of its first-phase trial for…
The Market Herald Video

" Immutep (ASX:IMM) publishes “favourable” interim data from second-phase efti trial

Immutep (ASX:IMM) has published new interim data from Part A of its second-phase TACTI-002 trial showing…

" Microba Life Sciences (ASX:MAP) partners with Midnight Health

Microba Life Sciences (ASX:MAP) has signed a strategic partnership agreement with healthcare company, Midnight Health, to…